#ASH18: Blue­bird and Cel­gene didn’t 'break' their next-gen BC­MA CAR-T, so now they’ll dou­ble down on the dose and root for re­al dura­bil­i­ty

5 years ago
R&D

#ASH18: Gilead posts im­pres­sive sur­vival rates for Yescar­ta — but sales re­main lean

5 years ago
R&D

#ASH18: Cel­gene of­fers up a stel­lar com­plete re­sponse rate for JCAR017. Will any­one no­tice?

5 years ago
R&D

#ASH18: Re­gen­eron's bis­pe­cif­ic REGN1979 of­fers eye-catch­ing 80% CR rate in fol­lic­u­lar lym­phoma, spurring swift shift to piv­otal study

5 years ago
R&D

#ASH18: Ac­celeron and Cel­gene take cen­ter stage with a pair of PhI­I­Is for lus­pa­ter­cept they be­lieve will back up $2B-plus in rev­enue pro­jec­tions

5 years ago
R&D

Amarin just rolled out a bat­tery of promis­ing new da­ta for Vas­cepa — brace your­self for the M&A chat­ter to come

5 years ago
R&D

In­novent, Eli Lil­ly cite a new suc­cess for their PD-1 in lung can­cer, with a like­ly pi­o­neer­ing ap­proval in Chi­na loom­ing

5 years ago
R&D
China

Ex-Ker­ris­dale an­a­lyst sets out to tor­pe­do Nek­tar with a blunt short at­tack on star drug NK­TR-214: 'It doesn’t work'

5 years ago
Pharma

GSK-backed sci­en­tif­ic team at UCSF says they found the im­mor­tal­i­ty switch in can­cer cells — and know how to turn it off

5 years ago
Discovery

David Schenkein is pass­ing the reins at Agios to Jack­ie Fouse af­ter a star-mak­ing 10-year run

5 years ago
People

Y-mAbs’ sto­ry comes in­to the light: a ship­ping ty­coon, the MSK re­searcher, a par­tial hold and a $92M IPO gam­ble

5 years ago
Financing

The biotech mood at the halfway mark of 2018? Bois­ter­ous, fo­cus­ing more at­ten­tion on Chi­na and look­ing for ac­cel­er­at­ed progress

5 years ago
Special

Bio­gen's high-stakes Alzheimer's gam­ble is be­ing roast­ed by the ex­perts. Is the amy­loid be­ta the­o­ry dead?

5 years ago
R&D
Pharma

Tom Hugh­es jumps ship at Zaf­gen and gets back to the helm of a note­wor­thy biotech

5 years ago
People

Game change: Pfiz­er dou­bles down on its late-stage pipeline as CEO Read dis­avows a long re­liance on M&A deals

5 years ago
Deals
R&D

7 things you need to know now about rais­ing biotech cash in Chi­na (Part 1)

5 years ago
Financing
China

The un­der-40s: How does the next gen­er­a­tion of bio­phar­ma ex­ec­u­tives view the fu­ture?

6 years ago
People
Special

New year, new tax rates. How did the world’s biggest drug­mak­ers fare?

6 years ago
R&D

The End­points 100: Biotech ex­ecs stam­pede in­to 2018 with a cheer for the FDA and bull­ish feel­ings on pub­lic mar­kets, pri­vate in­vestors and a ‘hot’ M&A fu­ture

6 years ago
Deals
Pharma

Top 10 pipeline blowups, set­backs and sna­fus in H2 2017

6 years ago
Bioregnum
R&D

The End­points 11: A group of dis­rup­tive up­starts on a do-or-die mis­sion to launch new meds

6 years ago
Startups
Special

The top 10 bio­phar­ma CROs in the world—mid-2017 edi­tion

6 years ago
Deals
Outsourcing

Top 10 pipeline blowups, set­backs and sna­fus in H1 2017

6 years ago
R&D
Special
First page Previous page 239240241242
A service from the Financial Times